#uthr

Motley Fool: United Therapeutics Corporation (UTHR) 2019 Q2 Earnings Call Transcript

Image source: The Motley Fool.

United Therapeutics Corporation (NASDAQ:UTHR) Q2 2019 Earnings Call July 31, 2019, 9:00 a.m. ET

Contents:

Prepared Remarks

Questions and Answers

Call Participants

Trending

Prepared Remarks:

Operator

Good morning, and welcome to the United Therapeutics Corporate second quarter 2019 earnings call. My name is Michelle, and I will be your conference operator today.…

Motley Fool: Here’s Why United Therapeutics Fell 18.1% in May

What happened

Shares of United Therapeutics (NASDAQ:UTHR) fell more than 18% last month, according to data provided by S&P Global Market Intelligence. The specialty pharmaceutical company reported first-quarter 2019 operating results that showed the business faces persistent headwinds. Revenue declined roughly 7% year over year, while an $800 million up-front payment to Arena Pharmaceuticalsfor…

Analyst Activity – Wedbush Reiterates Outperform on United Therapeutics Corporation (NASDAQ:UTHR)

Analyst Ratings For United Therapeutics Corporation (NASDAQ:UTHR) Today, Wedbush reiterated its Outperform rating on United Therapeutics Corporation (NASDAQ:UTHR) with a price target of $229.00. There are 1 sell rating, 6 hold ratings, 5 buy ratings on the stock. The current consensus rating on United Therapeutics Corporation (NASDAQ:UTHR) is Hold (Score: 2.33) with a consensus target price of…

New Post has been published on http://www.stockmarketsdaily.com/overvalued-stock-united-therapeutics-corporation-nasdaquthr/14837/

Overvalued Stock: United Therapeutics Corporation (NASDAQ:UTHR)

(adsbygoogle = window.adsbygoogle || []).push();

We look at United Therapeutics Corporation (NASDAQ:UTHR) a company in the Healthcare industry getting a lot of attention at the moment, to assess if it provides value for investors considering buying or selling it. Currently United Therapeutics Corporation is trading at $182.50 after moving down -0.65% in the previous day of trading. [Trend Analysis]

UTHR is trading with a trailing 12 month P/E multiple of 53.99 and an estimated forward P/E multiple of 15.14. The stock has an estimated 5 year annual growth of 19.56% and a PEG multiple of 2.76.

Rather than the usual Price to Earnings (P/E) multiple method, we use a slightly different method to assess if United Therapeutics Corporation is potentially a value buy for investors, the PEG ratio (P/E to growth). This PEG multiple takes into account the expected long term growth in earnings of the company rather than merely the growth for one earnings period ahead as forward P/E does.

That is to say, P/E simply doesn’t account for the long term prospects of UTHR. As a rule of thumb, a stock with a PEG of between 0 and 1 is usually considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced. Based on the PEG ratio of UTHR being 2.76, we consider United Therapeutics Corporation to likely be overpriced.

This analysis means that value buyers who do not currently hold United Therapeutics Corporation (NASDAQ:UTHR) should not consider buying and investors currently holding the stock should consider selling.

omg I feel so dumb now .__.

oh. aah don’t be sorry! I can’t communicate T^T